Selective JAK Inhibitor Compound for Autoimmune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current JAK inhibitors have limitations in effectively treating inflammation, autoimmune diseases, transplant rejection, and other conditions related to cartilage turnover impairment and hypersecretion of IL6, necessitating the development of more potent and selective JAK inhibitors.
Innovation Solution
A compound of formula (I) or its pharmaceutically acceptable salt, which is a selective JAK inhibitor, is developed, featuring specific structural units and substituents that enhance its therapeutic efficacy in treating inflammatory and autoimmune diseases by selectively targeting JAK pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing JAK inhibitors are used, then some therapeutic effect is achieved, but the potency and selectivity are insufficient for effectively treating inflammation and autoimmune diseases
Solution Approach 1:
The patent modifies molecular parameters including the core heterocyclic structure (pyrrolo[2,3-d]pyrimidine), substituent types (halogen, alkyl, aryl groups), and positional arrangements to optimize JAK inhibition potency and selectivity while maintaining manageable structural complexity
Solution Approach 2:
The compound combines multiple functional groups (heterocyclic core, amino substituents, aryl groups) into a composite molecular structure that achieves enhanced therapeutic efficacy through synergistic interactions of different structural elements
2Measurement precision
If current JAK inhibitors are administered, then some symptom relief is provided, but the selectivity for specific JAK pathways is insufficient
Solution Approach 1:
The patent introduces specific local structural features including halogen substituents at particular positions, specific heterocyclic core configurations, and targeted amino group placements to enhance binding selectivity for specific JAK isoforms while maintaining overall structural manageability
3Reliability
If more potent JAK inhibitors are developed, then therapeutic benefits improve, but the risk of side effects and toxicity may increase
Solution Approach 1:
The patent utilizes structure-activity relationship principles to optimize the molecular structure such that enhanced potency is achieved through specific structural features (heterocyclic core, substituent patterns) that simultaneously improve selectivity, thereby reducing off-target effects and toxicity while maintaining or enhancing therapeutic benefit
Data Source
AI summary
The present invention discloses a series of JAK inhibitors, and particularly discloses a compound of formula (I) or a pharmaceutically acceptable salt thereof and the use thereof in preparation of drugs for treating diseases related to JAK.